Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

NCT03745651 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03745651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03745651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 20, 2018
Completion date
November 9, 2020
Enrollment
618 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis